吡氧噻嗪对小鼠S180移植性肿瘤的抑制作用及其对COX-2及VEGF、FGF-2、MVD表达的影响  

Inhibitory effects of piroxicam on the transplanted sarcoma S180 of mice and its effect on the expression of COX-2,VEGF, FGF-2 and MVD

作　　者：高雪芹[1,2] 张维东[1,2] 宋守芹[1,2] 王丽[1,2] 黄海燕[1,2] 

机构地区：[1]山东省医学科学院医药生物技术中心 [2]山东省医学科学院基础医学研究所250062

出　　处：《中国药理学通报》2002年第4期426-429,共4页Chinese Pharmacological Bulletin

摘　　要：目的　探讨吡氧噻嗪对S180肉瘤细胞的抑制作用及其对肿瘤组织COX 2、VEGF、FGF 2、及微血管密度的影响。方法　昆明种小鼠随机分为对照组、FT2 0 7组、吡氧噻嗪 5、2 5、1mg·kg-1,于接种S180后d 2开始灌胃给药 ,连续 9d观察抑瘤率 ,并采用免疫组化的方法研究吡氧噻嗪对肿瘤组织COX 2及血管相关生长因子的作用。结果　吡氧噻嗪大、中、小 3个剂量组均有明显的抑瘤作用 ,抑瘤率分别为31 4 %、4 0 7%和 34 9%。免疫组化染色显示吡氧噻嗪对肿瘤组织的COX 2表达有抑制作用 ,同时血管生长相关因子VEGF、FGF 2表达也明显下调 ,MVD明显降低。结论　吡氧噻嗪对S180有抑制作用 ,它可抑制肿瘤组织COX 2的表达。COX 2表达与血管生长相关因子有关。吡氧噻嗪可通过抑制COX 2的表达而抑制肿瘤血管的生长 ,进而抑制肿瘤的生长。AIM To investigate the effects of piroxicam on transplanted Sarcoma S180 and the expression of COX 2,VEGF,FGF 2 and microvessel density (MVD) in tumor tissue METHODS Kunming mice were randomizedly divided into control group, FT207 positive group and 5, 2 5, 1 mg·kg -1 piroxicam groups One day after inoculation of 0 2 ml S180 cell suspension, FT207 and piroxicam were given by gastric intubation for 9 days The inhibitory rate on S180 was calculated routinely The expression of COX 2,VEGF,FGF 2 and MVD was detected by immunohistochemistry RESULTS The growth of S180 was significantly inhibited by piroxicam at the doses of 5, 2 5, 1 mg·kg -1 with the inhibitory rate of 31 4%,40 7% and 34 9% respectively The expression of COX 2 in the tumor tissue was also inhibited by piroxicam. Accordingly the expression of VEGF,FGF 2 and MVD was markedly inhibited in dose dependent manner by piroxicam CONCLUSIONS The results suggest that piroxicam has inhibitory effects on S180,and it also decreases the expression of COX 2 in tumor tissue. There is a relation ship between the expression of COX 2 and angiogenesis related factor Antiangiogenesis may be another mechanism for piroxicam to exert its chemopreventive and treatment effects.

关 键 词：吡氧噻嗪 小鼠 S180移植性肿瘤 抑制作用 COX-2 VEGF FGF-2 MVD 

分 类 号：R971.1[医药卫生—药品] R73－354[医药卫生—药学]